US PTAB Patent Cases
8,574 decisions indexed
Page 133 of 286 · 8,574 total
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,049,652 covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description, lack of enablement, and obviousness of key mutants. The Board has not yet ruled on the petition.
TCL INDUSTRIES HOLDINGS CO., LTD. v.ATI Technologies ULC
TCL Industries and ATI Technologies filed a joint motion to terminate IPR 2024-00366 concerning U.S. Patent 8,760,454. The motion indicates a settlement and seeks to end the proceeding.
Micron Technology, Inc. et al. v.Netlist, Inc.
The PTAB instituted an inter‑partes review of Netlist’s ’608 memory‑module patent on claims 1‑5 after Samsung’s petition showed a reasonable likelihood of unpatentability under obviousness.
CADENCE DESIGN SYSTEMS, INC. v.Semiconductor Design Technologies, LLC
Cadence and Semiconductor Design Technologies have settled their dispute and jointly moved to terminate the IPR covering U.S. Patent 7,603,636, an electronic design automation patent.
Delta Power Equipment Corporation et al. v.P & F Brother Industrial Corporation
Delta Power Equipment, Lowe’s and Home Depot seek rehearing after the PTAB denied institution of an IPR on their cutting‑machine blade‑guard patent, arguing the Board misread the Gass prior art and that claims 1,2,5,9 are obvious.
CISCO SYSTEMS, INC. v.UMBRA TECHNOLOGIES LTD.
Cisco seeks Director Review of a PTAB decision that found Umbra's data‑beacon networking claims obvious. Umbra contends the Board misinterpreted the claim preamble and ignored key evidence, urging reversal of the unpatentability finding.
OneSource Solutions International, Inc. et al. v.Hippocratic AI, Inc.
OSSI has filed a PGR petition seeking cancellation of all 20 claims of Hippocratic AI’s 12,142,371 patent, alleging obviousness, lack of enablement, indefiniteness, and abstract‑idea ineligibility.
CISCO SYSTEMS, INC. v.UMBRA TECHNOLOGIES LTD.
Cisco responded to Umbra’s request for Director Review, arguing that the Board’s claim‑construction finding that the preamble “for providing data beacons” is non‑limiting is correct and that the request should be denied.
Therabody, Inc. v.DataFeel, Inc. et al.
Therabody has filed a post‑grant review petition seeking cancellation of DataFeel’s 12,036,174 patent covering percussive massage devices. The petition alleges obviousness over multiple prior‑art references and a lack of written description and enablement. It also argues the Board should not invoke the Fintiv discretionary denial provision.
Be Smarter, LLC et al. v.Yondr, Inc.
Be Smarter has filed a post‑grant review petition challenging Yondr’s ’078 patent covering locking cases for mobile devices, asserting anticipation, obviousness, indefiniteness, and lack of patent‑eligible subject matter.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories has filed a Post‑Grant Review petition seeking cancellation of claims 1‑10 of Seikagaku’s 11,959,109 patent covering recombinant endotoxin assay methods. The petition alleges lack of written description, lack of enablement, and anticipation by a 2019 publication.
CISCO SYSTEMS, INC. v.UMBRA TECHNOLOGIES LTD.
Cisco Systems challenged UMBRA Technologies’ ’632 patent on data‑beacon and SD‑WAN innovations. UMBRA’s response argues the cited ’421 patent and ’685 provisional lack the required disclosures and contain cancelled matter, rendering them non‑prior art. The patent owner also asserts the term “data beacon” is a limiting preamble limitation not taught by the prior art.
Samsung Electronics Co., Ltd. et al. v.Headwater Research LLC
Samsung and Google successfully oppose Headwater Research’s untimely Director Review request, leaving the PTAB’s finding that the ’733 patent’s claims are unpatentable intact.
RingConn, LLC v.Ouraring Inc. et al.
RingConn has filed a post‑grant review petition seeking cancellation of all 18 claims of Oura’s wearable ring patent, alleging obviousness over multiple prior‑art references and §112 defects. The petition also argues the Board should not deny institution under §325(d) or §314(a).
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a PGR petition challenging Halozyme’s U.S. Patent 12,110,520 covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description, lack of enablement, and obviousness over prior art. The Board has not yet ruled.
Phison Electronics Corporation v.Vervain, LLC
Phison Electronics Corp. petitions the PTAB to invalidate Vervain’s ‘370 hybrid NAND‑flash patent, asserting lack of written description, indefiniteness, and obviousness over prior art. The petition targets claims 1‑18 and seeks cancellation under §§ 112(a), 112(b), 103 and 101. Institution of the review is pending.
Phison Electronics Corporation v.Vervain, LLC
Phison Electronics Corp. has filed a post‑grant review petition seeking cancellation of ten claims of Vervain’s ‘369 NAND‑flash patent, alleging abstractness, lack of written description, indefiniteness, and obviousness over prior art.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a PGR petition challenging Halozyme’s 13 claims covering PH20 hyaluronidase variants, asserting lack of written description, enablement, and obviousness. The petition seeks to have the claims declared unpatentable.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s broad PH20 hyaluronidase patent, asserting lack of written description, enablement, and obviousness of the claimed protein variants.
SCIENTIFIC DRILLING INTERNATIONAL, INC. v.Gunnar LLLP
Scientific Drilling International has filed a Post‑Grant Review petition seeking to invalidate all 22 claims of Gunnar LLLP’s ‘780 patent on magnetic ranging while drilling. The petition alleges lack of written description, indefiniteness, and obviousness over several prior‑art patents.
Microchip Technology, Inc. v.Aptiv Technologies AG et al.
The PTAB Director has acknowledged a Director Review request in IPR2024-00495 and limited the petitioner’s response to a 15‑page brief filed within five business days, prohibiting new evidence or additional briefing.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
Catalyst OrthoScience has petitioned the PTAB to institute a post‑grant review of Shoulder Innovations' reverse shoulder implant patent, asserting obviousness over six prior‑art references and indefiniteness of key claim terms.
Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.
Simpson Strong‑Tie has filed a petition to have the PTAB institute review of U.S. Patent 11,920,339, asserting lack of written description, indefiniteness, and obviousness over a suite of prior‑art hangers. The petition seeks institution of post‑grant review for all 31 claims.
Microchip Technology, Inc. v.Aptiv Technologies AG et al.
Aptiv Technologies seeks Director review of the PTAB’s decision that claims 13 and 14 of its automotive connectivity patent are unpatentable. The owner contends the Board misapplied the particularity requirement, shifted the burden of proof, and ignored secondary‑considerations evidence. The request targets the Board’s Final Written Decision.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
Catalyst OrthoScience seeks a PTAB post‑grant review of Shoulder Innovations' reverse shoulder implant patent, arguing obviousness over multiple prior‑art references and indefiniteness of the term “central channel.” The petition also asserts that discretionary denial is unwarranted.
SHENZHEN PINCAN TECHNOLOGY CO., LTD v.The Ridge Wallet LLC
The IPR concerning Ridge Wallet's patent 10,791,808 was terminated after the parties reached a confidential settlement. The Board granted the joint motion to terminate and ordered the settlement kept separate from the patent file.
3D Diagnostix, Inc. v.Watson Guide IP, LLC
3D Diagnostix petitions the PTAB to invalidate 13 claims of Watson Guide IP’s dental guide patent, alleging lack of written description, indefiniteness, and obviousness over multiple prior‑art references.
VIVITRO LABS INC. v.BIOMEDICAL DEVICE CONSULTANTS & LABORATORIES OF COLORADO, LLC
Vivitro Labs and the patent owner settled their IPR dispute over a biomedical device patent, leading the Board to terminate the proceeding and keep the settlement confidential.
Microchip Technology, Inc. v.Aptiv Technologies AG et al.
The Director denied Microchip Technology's request for review of the institution decisions that had denied institution of its IPRs against Aptiv's vehicle communication patent. The denial leaves the institution denials intact.
Microchip Technology, Inc. v.Aptiv Technologies AG et al.
Microchip Technology has filed a Director Review request to overturn PTAB’s denial of institution in two IPRs covering its USB‑hub patent. The petitioner alleges the Board failed to apply an agreed claim construction and ignored prior‑art analysis. The request is pending review by the Director.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.